Results:
Marked differences in ocular anterior segment biodisposition were apparent among the antagonists. Despite the high doses employed (1%), the EP1 (SC-51322) and the EP3 (L-826266) antagonists were essentially absent from the aqueous humor and iris/ciliary body. All antagonists, were still present at 24 hours post-dosing, except for the DP1 antagonist BW-A868C , SC-51322 and L-826266 The FP antagonist (AS-604872) preferentially accumulated in the palpebral conjunctiva to an extent where any effects on endogenous PGF present in the outflow pathways could be difficult to block with the concentrations of AS-604872 achieved in the ciliary body and aqueous humor. Considering the bioavailability and potencies of the antagonists at EP2 (PF-04418948), EP4 (GW-627368 ), and IP (RO-3244019) receptors, it could be confidently concluded that these receptors play no significant role in regulating IOP. There are implications beyond studying IOP , SC-51322 and L-826266 levels were relatively low and transient in the cornea .